Guoxin Securities released a research report on April 15 stating that it maintains the Australian and Chinese endoscopy (688212.SH) purchase rating. The main reasons for the rating include: 1) excellent performance in 2023, with rapid improvement in installed capacity of middle and high-end products; 2) increased profitability and increased investment in sales expenses; 3) focus on innovative research and development, continuing to enrich the product line; 4) equity incentives for the second time after launch, demonstrating confidence in development. (Mainichi Keizai Shimbun)
国信证券4月15日发布研报称，维持澳华内镜（688212.SH）买入评级。评级理由主要包括：1）2023年业绩表现亮眼，中高端产品装机快速提升；2）盈利能力提升，销售费用投入力度加大；3）聚焦创新研发，产品线持续丰富；4）推出上市后第二次股权激励，彰显发展信心。（每日经济新闻）
Guoxin Securities released a research report on April 15 stating that it maintains the Australian and Chinese endoscopy (688212.SH) purchase rating. The main reasons for the rating include: 1) excellent performance in 2023, with rapid improvement in insta
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.